This content is for members only. Visit the site and log in/register to read.

In episode 585, Mike and James finally get back to being PREMIUM. We review the REDUCE-AMI trial which tried to answer the question – do you need to use a beta-blocker after an MI if there is preserved ejection fraction? We also review a COPD trial that shows integrating respiratory specialists in primary care improves guideline adherence. However, the interesting finding is what happens to the quality-of-life change and hospitalizations. The results of both of these trials may surprise you.

Show notes

2) Cluster randomised controlled trial of specialist-led integrated COPD care (INTEGR COPD)

In episode 571, James and Mike talk about 2 new papers – we learn what antibiotics we can use for community-acquired pneumonia and we also talk about the prevalence and management of dyslipidemia in Canadian primary care practices and find out who has this problem and who gets treated.

Show Notes

Prevalence and management of dyslipidemia in primary care practices in Canada

In episode 550, James and Mike talk in a PREMIUM way about a new cholesterol lowering agent. Bempedoic acid is nothing tremendously exciting but what was very interesting was a subsequent publication that looked at a primary subset analysis, yet completely left out the secondary subset data. Have a listen and find out why.

Show Notes

Sensible Medicine

MyStudies

CFPC Learn

PEIP conference Oct 20-21, 2023

In episode 539, James and Mike focus in a PREMIUM way on the latest prostate cancer intervention trial. Patients with prostate cancer were randomized to active monitoring, surgery, or radiotherapy and followed for 15 years to see which was the best option. Have a listen and hear what was found.

Show Notes

1) Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

2) Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment